MitoQ supplement for frailty and memory problems in older adults
Tests MitoQ on blood vessels, movement and thinking in frail older adults.
Key facts
- Who runs it
- UConn Health
- Where
- Farmington, United StatesSee the site
- Trial code
- Registry title
- The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 7 Oct 2024
- Expected to end
- 1 Feb 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Mitoquinone Mesylate
- Placebo capsule
- Record updated
- 12 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 65-80 who walk slowly and/or have mild memory and thinking problems (mild cognitive impairment), and who have good heart and blood vessel health.
- Age
- 65 to 80 years
- Sex
- Men and women
- Disease stage
- Slow walking speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment.
- Earlier treatment
- People cannot join if they take medicines that change blood pressure, blood flow or metabolism. They also cannot join if they ever had chemotherapy or radiotherapy, or took immune-changing medicines such as high-dose corticosteroids in the past 6 months.
- Biomarker or test result
- Heart tracing (ECG) QTc must not be above 450 ms in men or above 460 ms in women.
Main reasons for not taking part
- Weak immune system, including HIV infection, or a vaccination in the past two weeks or an infection in the past three weeks
- Taking warfarin or another blood thinner, or a known bleeding disorder
- Diabetes that needs insulin
- Past ventricular arrhythmia (a dangerous fast heart rhythm)
- Serious illness or hospital stay in the past 3 months, advanced nerve disease, terminal illness or a recent fall
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment
- good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)
Who cannot take part
- Recent acute infection three weeks prior to enrollment
- Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids
- On warfarin or other medications that are considered a blood thinner
- Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
- Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
- Severe autoimmune disease requiring biological therapy
- Major severe illness and/or Hospitalization in past 3 months
- Recent fall or other conditions that will impair ability to complete and/or interpret mobility performance test
- Known bleeding disorder
- Any conditions that would impair the function to perform grip strength test
- include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study
- Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)
- Baseline ECG QTc >450 ms in men and QTc >460 ms in women
- A vaccination in past two weeks
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 80 years old?
Where in United States
- UConn HealthFarmington, United StatesContact: George Kuchel, MDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question[s] it aims to answer are:
Read full original descriptionShow less
* To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
The 2 groups in the trial
- Placebo capsulePlacebo, for comparison
Gelatin capsules
- MitoQ capsuleTreatment being tested
Capsules containing mitoquinone mesylate (MitoQ, 5 mg/capsule) totaling 20 mg taken every day for 12 weeks.
Treatment: Mitoquinone Mesylate
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
- Plain-language title
- MitoQ supplement for frailty and memory problems in older adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT06027554, who can take part
- Record updated
- 12 August 2026